Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04031729 · ClinicalTrials.gov registry record · Phase 1
Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT04031729: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT04031729 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04031729, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the United States. A proportion of people with NAFLD will develop progressive, inflammatory nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis and liver failure. NAFLD is expected to be the most common indication for liver transplantation by the year 2020. We hypothesize that among adults with NAFLD, aspirin will reduce intrahepatic lipid content, as quantified by 1H magnetic resonance spectroscopy (1H-MRS).
Interventions
- DRUG Placebo oral tablet
- DRUG Aspirin 81 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-09-12 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04031729
The ClinicalTrials.gov registry entry for NCT04031729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04031729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04031729 about?
NCT04031729 is a clinical study titled "Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease". Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the United States. A proportion of people with NAFLD will develop progressive, inflammatory nonalcoholic steatohepatitis (NASH), wh...
What is the current status of trial NCT04031729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2019-09-12. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT04031729?
The interventions under investigation include: Placebo oral tablet (DRUG), Aspirin 81 mg (DRUG).
Who is sponsoring clinical trial NCT04031729?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.